More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints
IMpower133 trial combining Tecentriq with chemotherapy in first-line small cell lung cancer met both its OS and PFS endpoints.
You may also be interested in...
Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.
Roche's combination of Tecentriq with chemotherapy is ahead of rivals in first-line SCLC and has been filed with the US FDA.
In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.